Hemospermia after transrectal ultrasound (TRUS)‎-guided prostatic biopsy : a prospective study

Abstract EN

Trans-rectal Ultrasound (TRUS) is a safe, cost-effective, radiation free imaging modality for evaluation of prostate.

But unfortunately, hemospermia is known to be associated with TRUS–guided prostate biopsy.

This study measured the incidence risk factors of hemospermia in patients undergoing trans-rectal ultrasonography TRUS.

A prospective observational study involving patients undergoing TRUS for suspected prostate cancer has been conducted at Al-Hussein and Sayed Galal, University Hospitals.

40patients were included in the study.

The results showed that 18 out of 40 patients (45 %) undergoing TRUS-guided prostatic biopsy, who were able to ejaculate, experienced hemospermia, which was associated with some degree of anxiety.

The mean duration of hemospermia was 4 (±1.4) weeks.

The number of ejaculations before the complete resolution of hemospermia was 6 (±5.6).

None of the clinical and pathological factors were significant predictors of the duration of hemospermia.